Shock Clinical Trial - Assessment of the Hemodynamic Effect of

Status Recruiting

Clinical Trial Summary

Through clinical cases or retrospective work with small sample size, some authors have observed an improvement in hemodynamic parameters, with a reduction or even withdrawal of norepinephrine after administration of a single dose of hydroxocobolamin (HCB) in refractory vasoplegic shock (cardiac surgery, liver transplantation and septic shock). HCB produces beneficial alterations in NO metabolism and may be suitable in vasoplegic syndrome. In addition, HCB seems to be involved in the elimination of hydrogen sulfide which also has an endogenous vasodilator function in the vascular endothelium. By these different actions it would cause vasoconstriction in vascular smooth muscle cells. Previous reports demonstrate that HCB was useful for refractory vasoplegic syndrome. The investigators will conduct a retrospective data collection of patients who was given intravenous HCB for refractory vasoplegic shock since January 2019.

Clinical Trial Description

Vasoplegic shock is defined by arterial hypotension, a high cardiac output with a normal or high cardiac index, collapsed systemic vascular resistance (SVR) and high dose of norepinephrine in the absence of hypovolaemia. The drop in secondary organ perfusion pressure ultimately leads to multiple organ failure and death. Through clinical cases or retrospective work with small sample size, some authors have observed an improvement in hemodynamic parameters, with a reduction or even withdrawal of norepinephrine after administration of a single dose of hydroxocobolamin (HCB) in refractory vasoplegic shock (cardiac surgery, liver transplantation and septic shock). HCB produces beneficial alterations in NO metabolism and may be suitable in vasoplegic syndrome. In addition, HCB seems to be involved in the elimination of hydrogen sulfide which also has an endogenous vasodilator function in the vascular endothelium. By these different actions it would cause vasoconstriction in vascular smooth muscle cells. Previous reports demonstrate that HCB was useful for refractory vasoplegic syndrome. The investigators will conduct a retrospective data collection of patients who was given intravenous HCB for refractory vasoplegic shock since January 2019. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04964492
Study type	Observational
Source	Centre Hospitalier Universitaire, Amiens
Contact	Pierre HUETTE, MD
Phone	03 22 08 78 99
Email	huette.pierre@chu-amiens.fr
Status	Recruiting
Phase
Start date	July 13, 2021
Completion date	October 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05898126` - Renin-guided Hemodynamic Management in Patients With Shock	N/A
Completed	`NCT05563701` - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting	`NCT05066256` - LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock	N/A
Not yet recruiting	`NCT06285513` - Cardiovascular Metabolic Remodeling in Shock
Not yet recruiting	`NCT05649891` - Checklists Resuscitation Emergency Department	N/A
Terminated	`NCT02755155` - Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients	Phase 4
Not yet recruiting	`NCT01941472` - Transcutaneous pO2, Transcutaneous pCO2 and Central Venous pO2 Variations to Predict Fluid Responsiveness	N/A
Terminated	`NCT01696175` - PICU Admission Lactate and Central Venous Oxymetry Study	N/A
Completed	`NCT01680783` - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure	N/A
Recruiting	`NCT01174966` - Assessment of Transcutaneous Oxygen Tension/Oxygen Challenge Test in Intensive Care Unit (ICU) Patients	N/A
Recruiting	`NCT01157299` - Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO	N/A
Completed	`NCT00743522` - Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication
Completed	`NCT03296891` - Point of Care Ultrasonography In The Management of Shock: A Pilot Study	N/A
Recruiting	`NCT05922982` - Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery	N/A
Withdrawn	`NCT04705701` - Comparing Post Cardiac Surgery Outcomes in ESRD Patient's With Early Dialysis Versus Standard Care	N/A
Recruiting	`NCT04615065` - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Completed	`NCT05330676` - Evaluation of Microcirculatory Function and Mitochondrial Respiration After Cardiovascular Surgery
Active, not recruiting	`NCT04079829` - Postoperative Respiratory Abnormalities
Completed	`NCT04089098` - VOLume and Vasopressor Therapy in Patients With Hemodynamic instAbility
Completed	`NCT03190408` - Variation in Fluids Administered in Shock

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Assessment of the Hemodynamic Effect of Hydroxocabalamin in Refractory Vasodilatory Shock — VASOKIT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms